Search

everythinglearnresearchcommunity

for

Search:↓

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The user underwent a hair transplant 11 months ago and is satisfied with the results, regaining confidence. Post-operation treatments included oral minoxidil, finasteride, dutasteride, vitamin supplements, and occasional QR678 injections.

The user has been treating hair loss for a year using Hims topical finasteride/minoxidil, derma stamping, and RU58841, with plans to continue and hopes for more significant results. They have noticed some small hair growth at the temples and will provide updates on their progress.

A 24-year-old male is considering a hair transplant after unsuccessful attempts with oral minoxidil, topical finasteride, ketoconazole shampoo, and lifestyle changes. He believes smoking and caffeine may worsen his hair loss and is looking into hair fibers for temporary coverage.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

A transgender individual began MTF HRT with estradiol and spironolactone at 39 and is monitoring hair regrowth before starting minoxidil. They are hopeful about not needing wigs permanently.

User applied Hims topical finasteride/minoxidil cocktail nightly, with weekly oil massages and ketoconazole shampoo. They also use vitamin D and biotin occasionally.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.